Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 23;218(6):e20210008. doi: 10.1084/jem.20210008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Li et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Cardioprotection of netrin-1 is ADORA2B dependent. (A) Surgery and netrin-1 treatment strategy. Recombinant mouse netrin-1 or PBS was given i.v. 5 min before reperfusion. (B) Infarct sizes of Adora2b^−/− mice compared with WT mice after IR surgery with NTN1 treatment or PBS control (n = 10 for Adora2b^−/− groups, n = 5 for WT groups; two-way ANOVA with Bonferroni post hoc tests). (C) Representative infarct staining results of Adora2b^−/− mice and WT mice. The infarct area is outlined by a green line, and the blue line marks the AAR (scale bar = 1 mm). (D) cTnI levels of Adora2b^−/− mice compared with WT mice after surgery and netrin-1 treatment (n = 10 for Adora2b^−/− group, n = 7 for WT group; two-way ANOVA with Bonferroni post hoc tests). (E) ADORA2B receptor antagonist PSB1115 and netrin-1 treatment strategy. Recombinant mouse netrin-1 or PBS was given i.v. 5 min before reperfusion. (F) Infarct sizes of PSB1115-treated mice compared with vehicle control group after IR surgery with or without netrin-1 treatment (n = 10 for PSB1115-treated group, n = 5 and 6 for vehicle control group; two-way ANOVA with Bonferroni post hoc tests). (G) Representative infarct staining results of PSB1115-treated group and vehicle group. The infarct area is outlined by a green line, and the blue line marks the AAR (scale bar = 1 mm). (H) cTnI levels of PSB1115-treated mice compared with vehicle control mice after surgery and netrin-1 treatment (n = 10 for PSB1115-treated group, n = 7 and 8 for vehicle control group; two-way ANOVA with Bonferroni post hoc tests). *, P < 0.05. Data are presented as mean ± SD.